Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | June 14, 2022 | June 16, 2022 |
| Provention Bio, Inc.PRVB · Entity 12101 | Director | July 19, 2018 | July 26, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 687,049 |
Ending reported balance
After 2022-06-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-14 · Other · Acquired 61,111 · Balance 738,611 Row 2 · 2022-06-14 · Tax withholding · Disposed 51,562 · Balance 687,049 F1: On June 14, 2022, the reporting person exercised a warrant to purchase 61,111 shares of the Issuers common stock for $2.70 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer withholding of 51,562 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,549 shares. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2022-06-15 | Direct | 0 |
Reported balance
After 2022-06-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-14 · Other · Disposed 61,111 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2022, the reporting person exercised a warrant to purchase 61,111 shares of the Issuers common stock for $2.70 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer withholding of 51,562 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,549 shares.
Provention Bio, Inc.
Report date July 19, 2018 · Filed July 26, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2023-07-03 | Direct | 504,668 |
Reported balance
After 2018-07-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-07-19 · Other · Acquired 504,668 · Balance 504,668 F1: Upon closing of the initial public offering of Provention Bio, Inc., a warrant was issued to MDB Capital Group LLC as partial consideration for services related to the offering. MDB Capital Group assigned a portion of that warrant to reporting person effective July 19, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the initial public offering of Provention Bio, Inc., a warrant was issued to MDB Capital Group LLC as partial consideration for services related to the offering. MDB Capital Group assigned a portion of that warrant to reporting person effective July 19, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2022 Filed Jun 16, 2022 16:01 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | OtherWarrants · Derivative | 61,111 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-22-037394 · doc4.xml · derivative · entry 3 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,111 shares Expires 2022-06-15 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:01 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 51,562 | $3.20 | $164,998.40 |
DisclosureSEC source: 0001209191-22-037394 · doc4.xml · nonDerivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,049 F1 · kind: On June 14, 2022, the reporting person exercised a warrant to purchase 61,111 shares of the Issuers common stock for $2.70 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer withholding of 51,562 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,549 shares. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:01 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | OtherCommon Stock | 61,111 | $2.70 | $164,999.70 |
DisclosureSEC source: 0001209191-22-037394 · doc4.xml · nonDerivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,611 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-22-001045 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:39 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0000899243-21-000701 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-03 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GiftCommon Stock | 271,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 4 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Julie Heider Nongrantor Pot Trust under the Julie Heider 2020 Irrevocable Trust Disclosed balance after: 271,000 Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GiftCommon Stock | 162,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 3 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Nongrantor Pot Trust under the Cameron Gray 2020 Irrevocable Trust Disclosed balance after: 162,600 Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GiftCommon Stock | 162,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Extended Family Nongrantor Pot Trust under the Cameron Gray 2020 Irrevocable Trust Disclosed balance after: 162,600 Read SEC document |
| December 02, 2020 Filed Feb 1, 2021 17:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GiftCommon Stock | 596,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003885 · doc5.xml · nonDerivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,300 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 16:13 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 5,000 | $15.30 | $76,500.00 |
DisclosureSEC source: 0000899243-20-026662 · doc4.xml · nonDerivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 to $15.30, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 16:13 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 5,000 | $15.00 | $75,000.00 |
DisclosureSEC source: 0000899243-20-026662 · doc4.xml · nonDerivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,500 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:54 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002058 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:37 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001326 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| July 19, 2018 Filed Jul 19, 2018 17:56 UTC | Provention Bio, Inc. PRVB · Entity 12101 | ConversionWarrant (right to buy) · Derivative | 144,824 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001493152-18-010235 · ownership.xml · derivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,824 Underlying: Common Stock, par value $0.0001 · 144,824 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: As previously reported on reporting person's Form 3 filed on July 3, 2018, upon consummation of the initial public offering of Provention Bio, Inc. (the "Issuer"), which closed on July 19, 2018, each share of Series A Preferred Stock will automatically convert into one share of Common Stock, par value $0.0001 per share ("Common Stock") and the Warrant will automatically convert into a warrant to purchase Common Stock. Read SEC document |
| July 19, 2018 Filed Jul 19, 2018 17:56 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 128,981 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001493152-18-010235 · ownership.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Underlying: Common Stock, par value $0.0001 · 128,981 shares Expires 2028-07-19 F2 · price: The securities were granted pursuant to the Issuer's 2017 Equity Incentive Plan, effective as of the closing of the Issuer's initial public offering of common stock. F1 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on January 19, 2018 and will become fully vested on July 19, 2022. Read SEC document |
| July 19, 2018 Filed Jul 26, 2018 20:00 UTC Amendment | Provention Bio, Inc. PRVB · Entity 12101 | OtherWarrant (right to buy) · Derivative | 504,668 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001493152-18-010543 · ownership.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,668 Underlying: Common Stock, par value $0.0001 · 504,668 shares Expires 2023-07-03 F1 · kind: Upon closing of the initial public offering of Provention Bio, Inc., a warrant was issued to MDB Capital Group LLC as partial consideration for services related to the offering. MDB Capital Group assigned a portion of that warrant to reporting person effective July 19, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:34 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037811 · doc4.xml · derivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2017 Filed Jan 28, 2019 16:40 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | OtherWarrants · Derivative | 192,495 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-19-005543 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,495 Underlying: Common Stock · 192,495 shares Expires 2022-12-14 F1 · kind: Upon closing of the initial public offering of the Issuer, the Warrants were issued to MDB Capital Group LLC ("MDB") as partial consideration for services as underwriter. MDB assigned a portion of the Warrants to the reporting person effective December 29, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.